Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1989-10-20
1991-07-23
Waddell, Frederick E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
5142262, 514318, 514646, A61K 31445, A61K 3154, A61K 31135
Patent
active
050344005
ABSTRACT:
This invention involves a method for reducing neurotoxic side effects that can be caused when NMDA antagonists such as MK-801 are used as anti-convulsants, to prevent excitotoxic damage in the central nervous system, or for anesthetic purposes in human or veterinary medicine. This method involves the use of anti-cholinergic agents such as scopolamine, atropine, benztropine, trihexyphenidyl, biperiden, procyclidine, benactyzine, or diphenhydramine in conjunction with, or subsequent to, administration of an NMDA antagonist. These anti-cholinergic agents greatly reduce or eliminate the deleterious side effects that can accompany NMDA antagonists (such as convulsion potentiating effects, as well as vacuole formation, mitochondrial dissolution, and possible death of cingulate/retrosplenial cerebrocortical neurons), without interfering with the useful properties of the NMDA antagonists. The protective agents described herein may also reduce the neurotoxic, psychotoxic, and/or hallucinatory side effects associated with illegal use of drugs such as phencyclidine.
This invention also relates to mixtures of NMDA antagonists and anti-cholinergic agents. Such mixtures can be used for beneficial purposes, such as providing safe anesthesia or ameliorating neurological disease processes, while also preventing deleterious side effects that might otherwise be caused by the NMDA antagonists.
REFERENCES:
patent: 2682543 (1951-05-01), Adamson et al.
patent: 2789110 (1957-04-01), Klavehn
patent: 2826590 (1958-03-01), Bottorff
patent: 2891890 (1959-06-01), Adamson
Boast, C. A., "Neuroprotection after brain ischemia: role of competitive NMDA antagonists," Neurology and Neurobiology 46: 691-698 (1988).
Clifford, D. B., et al., "Ketamine and MK-801 prevent degeneration of thalamic neurons induced by focal cortical seizures," Exp. Neurology 105: 272-279 (1989).
Olney, J. W., et al., "The Anti-Excitotoxic Effects of Certain Anesthetics, Analgesics and Sedative Hypnotics," Neuroscience Letters 68: 29-34 (1986).
Olney, J. W., et al., "MK-801 powerfully protects against N-methyl aspartate neurotoxicity," Eur J. Pharmacol 141: 357-361 (1987).
Olney, J. W., et al., "MK-801 prevents hypobaric-ischemic neuronal degeneration in infant rat brain," J. Neurosci. 9: 1701 (1989).
Olney, J. W., et al., "Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs," Science 244: 1360-1362 (1989).
Olney, J. W., et al., "Anti-Parkinsonian agents are phencyclidine agonists and N-methyl aspartate antagonists," Eur. J. Pharmacol. 142: 319-320 (1987).
Freedman, S. B., et al., "Muscarinic M1, M2 receptor binding; Relationship with functional efficacy," Eur. J. Pharmacol. 156: 133-142 (1988).
Waddell Frederick E.
Weddington Kevin
LandOfFree
Method for preventing neurotoxic side effects of NMDA antagonist does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing neurotoxic side effects of NMDA antagonist, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing neurotoxic side effects of NMDA antagonist will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-432515